Outpatient axicabtagene ciloleucel for relapsed/refractory large B-cell lymphoma: ZUMA-24 primary analysis

By afschroeder • September 16, 2025

Leslie LA, Baird JH, Flinn IW, Tees M, Hoda D, Deol A, Young P, McClune B, Varadarajan I, Essell J, Fanning S, Simmons G, Clark W, Rapoport AP, Rodriguez TE, Winters JN, Davis M, Miao HM, Ray M, Fang X, Kim JJ, Oluwole OO. Outpatient axicabtagene ciloleucel for relapsed/refractory large B-cell lymphoma: ZUMA-24 primary analysis. Am J Cancer Res. 2025 Aug 15;15(8):3417-3433. doi: 10.62347/GJNN1023. PMID: 40948517; PMCID: PMC12432568.

Tags: CAR-T, chimeric antigen receptor, Clinical Trial, Hematology/Oncology, Large B-cell lymphoma, outpatient, phase 2, Publications

Hyperferritinemia as a Clue to Neuroendocrine Carcinoma

Chao ES, Yoshikawa G, Qing X, Huang C. Hyperferritinemia as a Clue to Neuroendocrine Carcinoma. Cureus. 2025 Aug 13;17(8):e90020. doi: 10.7759/cureus.90020. PMID: 40951183; PMCID: PMC12431798.

Impact of Screening Mammography on Breast Cancer Outcomes in Women Aged 80 Years and Over

Huang SY, Murray M, Rubio A, Okoro N, Sedrak MS, McCloskey SA, Jackson N, Teshome M, Kapoor NS. Impact of Screening Mammography on Breast Cancer[...]

Identification of Targetable EGFR Mutations in Ovarian Cancer

Gower A, Win S, Ganguly R, Johnson M, Velez MA, Cummings AL, Lisberg A, Garon EB, Di Carlo B. Identification of Targetable EGFR Mutations in Ovarian Cancer.[...]